Search results for "Screen"

showing 10 items of 1374 documents

Newborn screening for 3-methylcrotonyl-CoA carboxylase deficiency: population heterogeneity of MCCA and MCCB mutations and impact on risk assessment.

2006

New technology enables expansion of newborn screening (NBS) of inborn errors aimed to prevent adverse outcome. In conditions with a large share of asymptomatic phenotypes, the potential harm created by NBS must carefully be weighed against benefit. Policies vary throughout the United States, Australia, and Europe due to limited data on outcome and treatability of candidate screening conditions. We elaborated the rationale for decision making in 3-methylcrotonyl-coenzyme A (CoA) carboxylase deficiency (MCCD), which afflicts leucine catabolism, with reported outcomes ranging from asymptomatic to death. In Bavaria, we screened 677,852 neonates for 25 conditions, including MCCD, based on elevat…

ProbandMalemedicine.medical_specialtyGenotypePenetranceBiologyAsymptomaticRisk AssessmentCohort StudiesGenetic HeterogeneityNeonatal ScreeningInternal medicineGermanyGeneticsmedicineHumansExpressivity (genetics)Genetics (clinical)AllelesGeneticsNewborn screeningGenetic heterogeneityInfant Newborn3-Methylcrotonyl-CoA carboxylase deficiencymedicine.diseasePenetranceCarbon-Carbon LigasesInborn error of metabolismMutationFemalemedicine.symptomDeficiency DiseasesHuman mutation
researchProduct

Italian Euromelanoma Day Screening Campaign (2005-2007) and the planning of melanoma screening strategies.

2011

Although no study has definitively shown that unfocused screening of skin cancer is effective, many campaigns have been organized with the aim of increasing awareness on melanoma risk factors. The objective of this study was to analyse the results of the Skin Cancer Screening Day in Italy during the period 2005-2007, to determine the priorities for melanoma control plans in a Mediterranean country. A total of 5002 patients were screened by dermatologists in 31 cities. Individuals who considered themselves to have many naevi and those with a family history of melanoma showed a higher number of common and atypical naevi. Ten melanomas, 20 basal cell carcinomas and two squamous cell carcinomas…

Program evaluationMaleCancer ResearchSkin NeoplasmsTime FactorsEpidemiologyBasal CellpreventionRisk Factorsself-surveillance80 and overSettore MED/35 - Malattie Cutanee E VenereeMedicineMass Screeningmelanoma screening campaignMelanoma prevention strategy Melanoma risk factors Melanoma screening campaign Self-surveillance Skin cancerFamily historyYoung adultChildMelanomaAged 80 and overeducation.field_of_studyNevus Pigmentedskin cancerMelanomaMiddle AgedMALIGNANT MELANOMA; screeningPrognosisOncologyItalymelanoma; screening; risk factors; prevention; prognosisChild PreschoolCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyAdolescentPopulationmelanoma prevention strategy; melanoma risk factors; melanoma screening campaign; self-surveillance; skin cancermelanoma prevention strategyYoung AdultPigmentedHumansmelanoma prevention strategy; melanoma risk factors; melanoma screening campaign; skin cancer; self-surveillancePreschooleducationNevusSocioeconomic statusMass screeningAgedbusiness.industrymelanoma risk factorsscreeningCarcinomaPublic Health Environmental and Occupational Healthmelanoma risk factorInfantmedicine.diseaseDermatologyMALIGNANT MELANOMASquamous CellCarcinoma Basal CellSelf-ExaminationSkin cancerbusinessProgram Evaluation
researchProduct

Synthesis of Triazenoazaindoles: a New Class of Triazenes with Antitumor Activity

2011

Despite improvements in the treatment and prevention of cancer, the number of new diagnoses continues to rise; this has fuelled substantial interest in the development of new and effective chemotherapeutic agents. Compounds of the triazene class, such as dacarbazine, have been used in the clinical management of many cancer types including brain, leukemia, and melanoma. A new compound class bearing a triazenoazaindole scaffold was synthesized with the aim of identifying new antiproliferative agents. Compounds 5 a-g and 6 a-c were screened against a panel of human tumor cell lines, and two of them, 5 e and 5 f, showed cytotoxicity (GI(50) range: 2.2-8.2 μM) in all cell lines. These two compou…

Programmed cell deathIndolesToxicology and Pharmaceutics (all)DacarbazineAntineoplastic AgentsAntiproliferative activityPharmacologyEGF receptorsDrug Screening AssaysBiochemistryCell LineFlow cytometryCell Line TumorNeoplasmsDrug DiscoveryTriazenoazaindolemedicineHumansTriazeno derivativesGeneral Pharmacology Toxicology and PharmaceuticsCytotoxicityPharmacologyAntitumor agentsTumorEpidermal Growth Factormedicine.diagnostic_testChemistryMelanomaOrganic ChemistryCancerAntitumorTriazenoazaindoles; Dacarbazine; Antitumor Activitymedicine.diseaseErbB ReceptorsDacarbazineApoptosisCell cultureMolecular MedicineDrug Screening Assays AntitumorAntitumor ActivityTriazenesTriazenoazaindolesAntiproliferative activity; Antitumor agents; EGF receptors; Triazeno derivatives; Antineoplastic Agents; Cell Line Tumor; Dacarbazine; Drug Screening Assays Antitumor; Humans; Indoles; Neoplasms; Receptor Epidermal Growth Factor; Triazenes; Pharmacology Toxicology and Pharmaceutics (all); Organic Chemistry; Molecular MedicineReceptormedicine.drugChemMedChem
researchProduct

A high-throughput chemical screen in DJ-1β mutant flies identifies zaprinast as a potential Parkinson's disease treatment

2021

AbstractDopamine replacement represents the standard therapy for Parkinson’s disease (PD), a common, chronic, and incurable neurological disorder; however, this approach only treats the symptoms of this devastating disease. In the search for novel disease-modifying therapies that target other relevant molecular and cellular mechanisms, Drosophila has emerged as a valuable tool to study neurodegenerative diseases due to the presence of a complex central nervous system, the blood–brain barrier, and a similar neurotransmitter profile to humans. Human PD-related genes also display conservation in flies; DJ-1β is the fly ortholog of DJ-1, a gene for which mutations prompt early-onset recessive P…

Programmed cell deathParkinson's diseasePurinonesSistema nerviós central MalaltiesMutantProtein Deglycase DJ-1PharmacologyBiologymedicine.disease_causechemistry.chemical_compoundNeurologiaDopaminemedicineAnimalsPharmacology (medical)GPR35 agonistPharmacologyHigh-throughput screeningPhosphodiesteraseParkinson Diseasemedicine.diseaseOxidative StresschemistryParkinson’s diseaseDrosophilaOriginal ArticleZaprinastNeurology (clinical)Phosphodiesterase inhibitorZaprinastGPR35Oxidative stressmedicine.drug
researchProduct

Pyrazolo[3,4-h]quinolines promising photosensitizing agents in the treatment of cancer.

2015

A new series of pyrazolo[3,4-h]quinolines, heteroanalogues of angelicin was conveniently prepared with a broad substitution pattern. A large number of derivatives was obtained and the cellular photocytotoxicity was evaluated in vitro against 5 different human tumor cell lines with GI50 values reaching the nanomolar level (14.52e0.04 mM). Selected compounds were able to photoinduce a massive cell death with the involvement of mitochondria. Their photodamage cellular targets were proteins and lipids and they did not cause any kind of DNA photodamage. This latter event is of considerable importance in the modulation of long term side effects, generally associated with the use of classical furo…

Programmed cell deathPhotodynamic therapy; Antiproliferative activity; Photosensitizing agents; Reactive oxygen species; PUVA therapyPUVA therapymedicine.medical_treatmentPhotodynamic therapyAntineoplastic AgentsAntiproliferative activityPhotodynamic therapy Antiproliferative activity Photosensitizing agents Reactive oxygen species PUVA therapyMitochondrionPhotodynamic therapychemistry.chemical_compoundStructure-Activity RelationshipAngelicinCell Line TumorDrug DiscoverymedicineStructure–activity relationshipHumansCell ProliferationPharmacologyPhotosensitizing AgentsDose-Response Relationship DrugMolecular StructureCell growthOrganic ChemistryGeneral MedicinePhotosensitizing AgentSettore CHIM/08 - Chimica FarmaceuticaFurocoumarinsBiochemistrychemistryQuinolinesPyrazolesDrug Screening Assays AntitumorReactive oxygen speciesEuropean journal of medicinal chemistry
researchProduct

Identification of Plakortide E from the Caribbean Sponge Plakortis halichondroides as a Trypanocidal Protease Inhibitor using Bioactivity-Guided Frac…

2014

In this paper, we report new protease inhibitory activity of plakortide E towards cathepsins and cathepsin-like parasitic proteases. We further report on its anti-parasitic activity against Trypanosoma brucei with an IC50 value of 5 mu M and without cytotoxic effects against J774.1 macrophages at 100 mu M concentration. Plakortide E was isolated from the sponge Plakortis halichondroides using enzyme assay-guided fractionation and identified by NMR spectroscopy and mass spectrometry. Furthermore, enzyme kinetic studies confirmed plakortide E as a non-competitive, slowly-binding, reversible inhibitor of rhodesain.

ProteasesStereochemistrymedicine.medical_treatmentTrypanosoma brucei bruceiPlakortis halichondroidesPharmaceutical ScienceTrypanosoma brucei01 natural sciences570 Life sciencesDioxanesprotease inhibitor03 medical and health sciencesddc:593Drug DiscoverymedicineAnimalsHumansProtease Inhibitorscathepsinlcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)IC50030304 developmental biologyTrypanocidal agentrhodesainchemistry.chemical_classification0303 health sciencesProteaseAntiparasitic Agentsbiology010405 organic chemistryCommunicationplakortide Ebiology.organism_classificationCathepsinsTrypanocidal AgentsAntiparasitic agentProtease inhibitor (biology)Porifera0104 chemical sciencesCysteine Endopeptidasesslowly-binding reversible inhibitorEnzymelcsh:Biology (General)BiochemistrychemistryDrug Screening Assays Antitumor570 Biowissenschaftenmedicine.drug
researchProduct

Development of Novel Selective Peptidomimetics Containing a Boronic Acid Moiety, Targeting the 20S Proteasome as Anticancer Agents

2014

This paper describes the design, synthesis, and biological evaluation of peptidomimetic boronates as inhibitors of the 20S proteasome, a validated target in the treatment of multiple myeloma. The synthesized compounds showed a good inhibitory profile against the ChT-L activity of 20S proteasome. Compounds bearing a β-alanine residue at the P2 position were the most active, that is, 3-ethylphenylamino and 4-methoxyphenylamino (R)-1-{3-[4-(substituted)-2-oxopyridin-1(2H)-yl]propanamido}-3-methylbutylboronic acids (3 c and 3 d, respectively), and these derivatives showed inhibition constants (Ki ) of 17 and 20 nM, respectively. In addition, they co-inhibited post glutamyl peptide hydrolase act…

Proteasome Endopeptidase ComplexPeptidomimeticStereochemistryCell Survivalanticancer agents; boronates; bortemib; Docking studies; Peptidomimetics; inhibitor; proteasomesAntineoplastic AgentsSaccharomyces cerevisiaedocking studieBiochemistrySubstrate Specificitychemistry.chemical_compoundCell Line TumorDrug DiscoverymedicineMoietyHumansGeneral Pharmacology Toxicology and PharmaceuticsPharmacologychemistry.chemical_classificationBinding SitesproteasomesBortezomibOrganic ChemistrybortezomibboronateBoronic AcidspeptidomimeticProtein Structure Tertiaryanticancer agentMolecular Docking SimulationinhibitorEnzymechemistryProteasomeBiochemistryDocking (molecular)Molecular MedicinePeptidomimeticsGrowth inhibitionDrug Screening Assays AntitumorProteasome InhibitorsBoronic acidmedicine.drug
researchProduct

Extracellular loop 2 of G protein-coupled olfactory receptors is critical for odorant recognition

2021

International audience; G protein-coupled olfactory receptors (ORs) enable us to detect innumerous odorants. They are also ectopically expressed in non-olfactory tissues and emerging as attractive drug targets. ORs can be promiscuous or highly specific, which is part of a larger mechanism for odor discrimination. Here, we demonstrate that the OR extracellular loop 2 (ECL2) plays critical roles in OR promiscuity and specificity. Using site-directed mutagenesis and molecular modeling, we constructed 3D OR models in which ECL2 forms a lid over the orthosteric pocket. We demonstrate using molecular dynamics simulations that ECL2 controls the shape and the volume of the odorant-binding pocket, m…

Protein Conformation alpha-HelicalOdorant bindingG protein[SDV]Life Sciences [q-bio]Mutagenesis (molecular biology technique)Molecular Dynamics SimulationLigandsReceptors OdorantBiochemistryMice[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyExtracellularOlfactory receptorAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyReceptorMolecular BiologyG protein-coupled receptorVirtual screeningmolecular modelingChemistryCell Biologyvirtual screeningLigand (biochemistry)Cell biology[SDV] Life Sciences [q-bio]Smell[SDV.AEN] Life Sciences [q-bio]/Food and NutritionOdorantsMutagenesis Site-Directedsite-directed mutagenesis[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Getting Docking into Shape Using Negative Image-Based Rescoring

2019

The failure of default scoring functions to ensure virtual screening enrichment is a persistent problem for the molecular docking algorithms used in the structure-based drug discovery. To remedy this problem, elaborate rescoring and post-processing schemes have been developed with a varying degree of success, specificity, and cost. The negative imagebased rescoring (R-NiB) has been shown to improve the flexible docking performance markedly with a variety of drug targets.The yield improvement is achieved by comparing the alternative docking poses against the negative image of the target protein’s ligand-binding cavity. In other words, the shape and electrostatics of the binding pocket is dir…

Protein ConformationComputer scienceGeneral Chemical EngineeringDrug Evaluation PreclinicalBinding pocketLibrary and Information SciencesCrystallography X-RayMachine learningcomputer.software_genre01 natural sciencesArticledrugsAutodock vinaUser-Computer InterfaceDOCK0103 physical sciencesVirtual screening010304 chemical physicsbusiness.industryDrug discoveryGeneral Chemistrymolecular dockingPANTHER/ShaEP-based R-NiB methodologyAutoDock0104 chemical sciencesComputer Science ApplicationsMolecular Docking SimulationBenchmarking010404 medicinal & biomolecular chemistryDocking (molecular)Artificial intelligencebusinesscomputer
researchProduct

A TR-FRET based functional assay for screening activators of CARM1

2013

Epigenome is an emerging field that demands selective cell-permeable chemical probes to perturb, especially in vivo, the activity of specific enzymes involved in modulating the epigenetic codes. Coactivator Associated Arginine (R) Methyltransferase 1 (CARM1) is a coactivator of estrogen receptor α (ERα), the main target in human breast cancer. We previously showed that overexpression of CARM1 by two-fold in MCF7 breast cancer cells increased the expression of ERα-target genes involved in differentiation and reduced cell proliferation, leading to the hypothesis that activating CARM1 by chemical activators may be therapeutically effective in breast cancer. Selective, potent, cell-permeable CA…

Protein-Arginine N-MethyltransferasesTime FactorsCARM1CARM1; arginine; FRET; methylation; PABP1High-throughput screeningEstrogen receptorarginineBacMamBreast NeoplasmsBiologyBiochemistryArticleEnzyme activatorCoactivatorFluorescence Resonance Energy TransferHumansEpigeneticsPABP1Molecular BiologyOrganic ChemistryFusion proteinEnzyme ActivationCARM1BiochemistryFRETMCF-7 CellsMolecular MedicineFemalemethylation
researchProduct